Gilder Gagnon Howe & Co’s Allogene Therapeutics ALLO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29	Closed	–	–	295
2021 Q4	$0	Hold	29	–	–	﹤0.01%	390
2021 Q3	$1K	Hold	29	–	–	﹤0.01%	421
2021 Q2	$1K	Hold	29	–	–	﹤0.01%	406
2021 Q1	$1K	Sell	29 -12	-29%	-$405	﹤0.01%	390
2020 Q4	$1K	Sell	41 -61,775	-100%	-$2.01M	﹤0.01%	336
2020 Q3	$2.33M	Sell	61,816 -98,704	-61%	-$3.72M	0.01%	234
2020 Q2	$6.87M	Buy	+160,520	New	+$5.81M	0.05%	166
2020 Q1	–	Sell	-2,182	Closed	-$57K	–	281
2019 Q4	$57K	Hold	2,182	–	–	﹤0.01%	275
2019 Q3	$59K	Hold	2,182	–	–	﹤0.01%	271
2019 Q2	$59K	Hold	2,182	–	–	﹤0.01%	278
2019 Q1	$63K	Sell	2,182 -41	-2%	-$1.19K	﹤0.01%	263
2018 Q4	$60K	Buy	+2,223	New	+$59.1K	﹤0.01%	256

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Gilder Gagnon Howe & Co's ALLO Position: Q1 2022 in Review

Gilder Gagnon Howe & Co sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 29 shares.

Gilder Gagnon Howe & Co first reported a position in ALLO in Q4 2018 and held it in 12 quarters. The position peaked at $6.87M in Q2 2020. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

Gilder Gagnon Howe & Co reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 29 Allogene Therapeutics shares in Q1 2022.
Gilder Gagnon Howe & Co first reported a position in Allogene Therapeutics in Q4 2018 and held it in 12 quarters.
Gilder Gagnon Howe & Co's Allogene Therapeutics position peaked at $6.87M in Q2 2020.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2022, filed 16 May 2022.